# The Next Frontier for Obesity Drugs Isn’t How Much Weight You Lose, but What Kind

> **Newsylist Open Intelligence Dossier** · First detected: 2026-10-01 14:29 UTC · Category: Business · Sources: 8 · Current Velocity: 5.66

## Intelligence Brief
"The Next Frontier for Obesity Drugs Isn’t How Much Weight You Lose, but What Kind" developed substantial multi-source reporting across the Business sector, tracked across 8 distinct newsrooms by Newsylist.


Key reporting was led by marketscreener.com, The Manila Times, Endpoints News and Chemical & Engineering News. Coverage velocity and cross-outlet momentum were measured using Newsylist open coverage telemetry.


Synthesized from multi-source international reporting and live coverage telemetry under Newsylist open intelligence methodology.

## Verified Facts & Key Claims
### What drove coverage for The Next Frontier for Obesity Drugs Isn’t How Much Weight You Lose, but Wha?
Coverage spiked when 8 independent newsrooms published 8 verified reports during this coverage cycle.

### How did Newsylist track this trend?
Newsylist monitored article arrival rates, source diversity, and cross-outlet validation in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| marketscreener.com | Weight-loss drug developers line up to tap lucrative market as competition heats up | 2026-10-01 00:00 | [Source Link](https://news.google.com/rss/articles/CBMi0gFBVV95cUxNbTNTUGFOUjd6M1R3QXpQNjZBcFM3LUVhX2lwN2tCYm9NaVhpLXdjRVEycGd3VUNaeEhQMi1VNTJPei03c3B0X1BGMGFSVlREdTVMdXA2STgxQk01b2Q2Sl9oa2VuVm5EbnpJOXJfRTl0TDdwc2xmQWtIWVc0MzF5SXpVZEZPTmI2Mk5ESHdtZDhsejltUDdaQ3h4MHdQS3pVTGRYb2JnZ21NOS1RNjF1Qm1KVXA2NEJhOEFwZkJaUHJaTlctai0wMW0zcmowVEtzRGc?oc=5) |
| The Manila Times | Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss | 2026-10-01 00:00 | [Source Link](https://news.google.com/rss/articles/CBMiqAJBVV95cUxPSjR0aGl1SXNudmx4Z0JTcU1mbzQtWEJpbUxBNE44TGlfbHR3UTdibkdIUG1qdmx6Y0h5SGU4NF9UbzFzWGZVSGUzZHB4UGdMbFBCeHlVWmRjMUtzMlJsZGFSNU5wN0dCcnl5bnpIT3R0eEgzOEVxSGlRR25rSHotanhxZzVySTJ6c0NZSUxDNm5DenhIVWJabGtPS201NzRpRnVpSGhFX3ZkTHNxZmdFZ2pWQ2k2bDEyUkQxakd2aXN1Yi01THRtUVYyRUJhb1lPTDQxc3hSZEZPR2hwWlpjOUt5QXhpcTVlU0d6dVY0Q1RxYkZETjlUMC1PQ1dRLWlNV3g1NXYycTFPem56ZDJzRVA3N0hvN0ozRUIwWFFBTmM2NkNxektYM9IBrgJBVV95cUxOWlNCM3RuXzB2dzVzalBBcW9STkpheGF5bnVmcGF6TS1iOXB) |
| Endpoints News | #EASD26: Regeneron’s antibody helps patients regain muscle after stopping GLP-1 therapy | 2026-10-01 00:00 | [Source Link](https://news.google.com/rss/articles/CBMirAFBVV95cUxPSi1MdDlFX2ViV0Z6WVlUM0U2T2loSEtVR2lYR0cyQlo3Q09sQXJQX1FzYW50WVpib0pScUI1NTZSeTJPNlJVZHhLZmVTQ0t3UUM5c005THcxUEdZMGNFOUFYVWdYNTk5QjJDUUFDUTdSN0t1akQ4QXdoMjFMUlUyVkZGUnJFUS1TMExyU3VUelNrT3VMTWUwdkF1WnlsZ1h2T092Zks3MzZKZ01G?oc=5) |
| Chemical & Engineering News | Pharma deals and data heat the weight-loss-drug market | 2026-10-01 00:00 | [Source Link](https://news.google.com/rss/articles/CBMingFBVV95cUxPUTJ2T0JFVE1DNFNlSlpJNU1KMGhVM0RfX1gza2NmcTVpMkdZZUc0RDM3X2FFQi1GX0VWSXNCOFNpaG85SXY0RmtJV1dON1Y5d1E4bDlFZUszSnI0SDdqbFBWbHFoUi1faENSMUprVE1ITFl6QzJKVzROSmNPbUxEemZVWFNfMnRnYktnSWNtNUlGMGNhMGxyU1RWaEdPQQ?oc=5) |
| Medical Xpress | Trevogrumab (anti-myostatin) can help preserve lean mass during and after semaglutide-induced weight loss | 2026-10-01 00:00 | [Source Link](https://news.google.com/rss/articles/CBMikAFBVV95cUxQWEVNelBFRTZMQzlnRU1rWFNDclJ4VzJxWndkZjd0bVExZURpbVl6T3JLODEwa1ZIS3JXS19SandzRUwxaW1RTXhQYi1PRzRuZGU4ZzB0SjI5T0xvbXpXODdGNHdMR1ppQ2ZYMkl3MHFOeW95ejVGNzNhQkhZenQ4RUwzYTZVS1lrekZjUXVMcnU?oc=5) |
| Seeking Alpha | Regeneron drug said to cut muscle loss when combined with Novo's semaglutide (REGN:NASDAQ) | 2026-10-01 00:00 | [Source Link](https://news.google.com/rss/articles/CBMiswFBVV95cUxOVGJDbEg0alhwT2dqV3hYOEJxMnZObmMtcksyc2NQLVpkSFFtWWpGd2hQenFnS2Z6YUFPSkM2d3RoMVo2UmVmUTNNcWczNkxITnZIdS15eXZ1LUdTaWN1ZlN5a1E4NGU4ampjZHJiTlJnTUNtRzBnSi02OUJjU3l2dWhpWFdKeFNtT1NaVnBpQ1dBcEFiY2VZMlNaU29BZThQQ0pQVi1Bb3hxRkhucUZNS3Q1cw?oc=5) |
| Reuters | Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial | 2026-10-01 00:00 | [Source Link](https://news.google.com/rss/articles/CBMi3wFBVV95cUxOdVh1MVVlR1NuWUV0UkNBY2o2V19FYy1oRU5jR2d5dWpINm9pcUQtZzVEZktPTDlpMmFDdWtnMkVUclJZZmh5LVFWU1VvcGRXOTRhWWJpVnNBTlhpY2U2amZhdjY1cFF2NU9YX0V3aHdfVkxiUVRoZXIydjdKaENBeFR4RW90NUxqQlJ6T3QtQUVKUG9udklMdzBYR3doMTJNV2JKZ0VrTkQ2OG9QNmdSanc5a1d1UEJqOUcwVlBnT2hFS2lvLXhjOFFYWkE0R1RySFdZazc3dU1DZUdHQUpn?oc=5) |
| WSJ | The Next Frontier for Obesity Drugs Isn’t How Much Weight You Lose, but What Kind | 2026-10-01 00:00 | [Source Link](https://news.google.com/rss/articles/CBMivwFBVV95cUxNU05vcmQzTm9tVTZ1TDZBLVl3LVBsTl9felUzTWVkVjY2Vk5uTHMyN1FxTUhjWmpFWDNSUzZTSUF3VjFYSkZNQjJiMXEtMGtxc3hINDFiT2dReVNqZUp6OXNVTEM3VlZQRGxlZ05LMy1fUWQ0d2FaUWxPOWpfUVNvdHROUWpjeGp5WklhZ0t1WXZQWTk1WW04cW91Qk5QWlM5TmFoNnJOSWx1NXJ6Yng5MC1nZ1E3Y1RTR2ViVERTRQ?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-10-01/the-next-frontier-for-obesity-drugs-isn-t-how-much-weight-you-lose-but-what-kind*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*